Conversion from apixaban to warfarin: Note: Apixaban affects the INR; measuring the INR during warfarin therapy may not be useful for determining an appropriate dose of warfarin. If continuous anticoagulation is necessary, discontinue apixaban and begin both a parenteral anticoagulant with warfarin when the next dose of apixaban is due; discontinue parenteral anticoagulant when INR reaches an. injection will partially reverse anticoagulation, though the levels of the individual factors will typically remain 20 % and larger doses should be given if possible (recommend 30ml/kg) For patients with prosthetic heart valves, full reversal of oral anticoagulants with vitamin K may result in prolonged oral anticoagulant resistance. For warfarin-treated patients who need to undergo a semiurgent (within 24–36 hours) procedure, low-dose oral vitamin K, given the day before the intervention, will often achieve sufficient INR correction and avoid the need for transfusion. In a study of 2 parallel cohorts of patients assessed in a perioperative anticoagulation management clinic, all patients had their warfarin held 5 days. This topic discusses risk factors for warfarin-associated bleeding and poor control of international normalized ratio (INR) targets. An approach to the management of a patient with warfarin-associated bleeding or an INR above the therapeutic range (ie, a supratherapeutic INR) is presented. The immediate reversal of these agents if life- threatening bleeding presents is indicated in an emergency setting. The anticoagulation and antiplatelet reversal strategies and agents will continue to evolve. Author Contributions All authors contributed equally to the manuscript. considerations when approaching anticoagulation reversal (back to contents) how coagulopathic is the patient? Critically ill patients often have several coagulopathies (e.g., thrombocytopenia plus supratherapeutic INR on warfarin). Consider all medications and coagulation labs in order to get a global sense of how coagulopathic the patient is. SUMMARY Warfarin (Coumadin®) is used to treat a number of hypercoagulable disease states. Since each patient responds differently to the same dose, this medication carries a high risk of bleeding. Some patients may ultimately require reversal with prothrombin complex concentrate (PCC), phytonadione (Vitamin K), fresh frozen plasma (FFP) or a combination of these agents. The Society of. Anticoagulation Reversal Guideline for Adults Antithrombotic reversal strategies should be limited to clinical situations (i.e. life-threatening bleeding) where the immediate need for anticoagulant reversal outweighs the risk of thrombosis (either from the reversal agent itself or normalization of coagulation in a patient with underlying thromboembolic risk). Warfarin (Coumadin) Anticoagulant reversal for life-threatening bleeds Video widget:YouTube|id=Qmgq0BvvZ7U References ↑ Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med.1994;120:897-902. ↑ Hylek, E et al. Acetaminophen and Other Risk Factors for Excessive Warfarin. Reversal of Anticoagulants Guidelines Contents [hide] Anticoagulant Reversal for IPH Guidelines For Reversal Of Anticoagulants Head Injury In Anticoagulated Patients UWMC-ML Cardiothoracic Surgery Perioperative Hemostasis Plan.